TapImmune

TapImmune reports positive immune responses in phase I cancer trial

Friday, January 16, 2015

TapImmune, an immunotherapy company, has reported the completion of data analysis from all 21 evaluable patients treated in a phase I clinical trial. In addition, the recent financing provides immediate, short term and long term access to the capital required to execute its exclusive option to license these very promising peptides and to progress its on-going clinical program into phase II trials.

[Read More]

Taplmmune, Aeras ink research collaboration

Thursday, November 3, 2011

TapImmune has signed a research collaboration with Aeras. The overall goal of this collaboration will be to evaluate the efficacy of TAP in concert with novel vaccine vectors encoding TB immunogens under development at Aeras with the aim of advancing suitable candidates to clinical development. Aeras will conduct all pre-clinical development studies at their laboratories in Rockville, MD.

[Read More]